Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

China NMPA accepts and grants priority review status to ArkBio's NDA for Azstarys to treat ADHD in patients aged six years and above: Shanghai, China Tuesday, June 17, 2025, 10:00 ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

The FDA has accepted for Priority Review the New Drug Application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia.

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced Tuesday that the U.S. Food and Drug Administration (FDA) granted priority review ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

Future Fund chair Greg Combet says institutions have to accept that the risks of investing in the US are rising whilst urging ...

PHILIPPINE President Ferdinand R. Marcos, Jr. will be reviewing the Konektadong Pinoy bill, a priority measure for his administration, amid concerns raised by telecommunications companies over some of ...